Appeal No. 2005-0027 Application No. 09/777,874 26. A method for reducing food consumption comprising administering to a subject in need thereof, an effective amount of the composition of Claim 11. 27. A method for reducing body weight comprising administering to a subject in need thereof, an effective amount of the composition of Claim 11. 28. A method for reducing serum triglycerides comprising administering to a subject in need thereof, an effective amount of the composition of Claim 11. 29. A method for treating hypertriglyceridaemia comprising administering to a subject in need thereof, an effective amount of the composition of Claim 11. 30. A method for treating hypercholesterolaemia comprising administering to a subject in need thereof, an effective amount of the composition of Claim 11. The prior art references cited by the examiner are: Wiegand 3,810,994 May 1974 Cavazza 4,268,524 May 1981 Stracher et al (Stracher) 5,008,288 April 1991 Burtle et al (Burtle) 5,030,657 July 1991 Moffett et al (Moffett) 5,536,516 July 1996 Hastings et al (Hastings) 5,626,849 May 1997 Wiener et al. (Weiner), “Liposomes as a Drug Delivery System,” Drug Development and Industrial Pharmacy, Vol. 15, No. 10, pp. 1523-1556 (1989) Grounds of Rejection 1. Claims 11-18, 20-27 and 311 stand rejected under 35 U.S.C. §103(a), as 1 In the final rejection, page 4 (Paper No. 8) claims 11-18 and 20-31 were rejected over Hastings in view of Weigand or Burtle. In the Answer, the examiner removed the rejection from claims 28-30. Answer, page 2. 2Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 NextLast modified: November 3, 2007